Biedermann N, Schnizer J, Lager D, Schnurch M, Stanetty C
J Org Chem. 2024; 89(8):5573-5588.
PMID: 38578036
PMC: 11040715.
DOI: 10.1021/acs.joc.4c00067.
Giulietti M, Piva F, Cecati M, Maggio S, Guescini M, Saladino T
Cells. 2024; 13(6.
PMID: 38534323
PMC: 10969587.
DOI: 10.3390/cells13060479.
Sonowal S, Gogoi U, Buragohain K, Nath R
Arch Microbiol. 2024; 206(3):122.
PMID: 38407579
DOI: 10.1007/s00203-024-03829-4.
Kaghad A, Panagopoulos D, Caballero-Garcia G, Zhai H, Britton R
Nat Commun. 2023; 14(1):1904.
PMID: 37019928
PMC: 10076431.
DOI: 10.1038/s41467-023-37346-7.
Mushtaq A, Zahoor A, Bilal M, Hussain S, Irfan M, Akhtar R
Molecules. 2023; 28(6).
PMID: 36985698
PMC: 10051988.
DOI: 10.3390/molecules28062722.
Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms.
Vicari H, Lima K, Costa-Lotufo L, Machado-Neto J
Cancers (Basel). 2022; 14(24).
PMID: 36551566
PMC: 9776580.
DOI: 10.3390/cancers14246080.
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B.
Nicolaou K, Pan S, Shelke Y, Rigol S, Bao R, Das D
Proc Natl Acad Sci U S A. 2022; 119(32):e2208938119.
PMID: 35930662
PMC: 9371655.
DOI: 10.1073/pnas.2208938119.
Synthesis and Biological Evaluations of Electrophilic Steroids Inspired by the Taccalonolides.
Clanton N, Hastings S, Foultz G, Contreras J, Yee S, Arman H
ACS Med Chem Lett. 2020; 11(12):2534-2543.
PMID: 33335677
PMC: 7734803.
DOI: 10.1021/acsmedchemlett.0c00534.
Structural simplification: an efficient strategy in lead optimization.
Wang S, Dong G, Sheng C
Acta Pharm Sin B. 2019; 9(5):880-901.
PMID: 31649841
PMC: 6804494.
DOI: 10.1016/j.apsb.2019.05.004.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer E, Rau R, Berg S, Liu X, Minard C, DAdamo D
Pediatr Blood Cancer. 2018; 65(8):e27066.
PMID: 29719113
PMC: 6019176.
DOI: 10.1002/pbc.27066.
Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis.
Crane E, Gademann K
Angew Chem Int Ed Engl. 2016; 55(12):3882-902.
PMID: 26833854
PMC: 4797711.
DOI: 10.1002/anie.201505863.
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.
Xiao Z, Morris-Natschke S, Lee K
Med Res Rev. 2015; 36(1):32-91.
PMID: 26359649
PMC: 4679534.
DOI: 10.1002/med.21377.
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
Dybdal-Hargreaves N, Risinger A, Mooberry S
Clin Cancer Res. 2015; 21(11):2445-52.
PMID: 25838395
PMC: 4812567.
DOI: 10.1158/1078-0432.CCR-14-3252.
Eribulin for advanced breast cancer: a drug evaluation.
Shablak A
J Breast Cancer. 2013; 16(1):12-5.
PMID: 23593076
PMC: 3625759.
DOI: 10.4048/jbc.2013.16.1.12.
Interactions of halichondrin B and eribulin with tubulin.
Bai R, Nguyen T, Burnett J, Atasoylu O, Munro M, Pettit G
J Chem Inf Model. 2011; 51(6):1393-404.
PMID: 21539396
PMC: 3130535.
DOI: 10.1021/ci200077t.
Modern natural products drug discovery and its relevance to biodiversity conservation.
Kingston D
J Nat Prod. 2010; 74(3):496-511.
PMID: 21138324
PMC: 3061248.
DOI: 10.1021/np100550t.
Second generation synthesis of C27-C35 building block of E7389, a synthetic halichondrin analogue.
Yang Y, Kim D, Kishi Y
Org Lett. 2009; 11(20):4516-9.
PMID: 19754145
PMC: 2759418.
DOI: 10.1021/ol9016589.
Tubulin-interactive natural products as anticancer agents.
Kingston D
J Nat Prod. 2009; 72(3):507-15.
PMID: 19125622
PMC: 2765517.
DOI: 10.1021/np800568j.
Effective Procedure for Selective Ammonolysis of Monosubstituted Oxiranes: Application to E7389 Synthesis.
Kaburagi Y, Kishi Y
Tetrahedron Lett. 2008; 48(51):8967-8971.
PMID: 19050739
PMC: 2180417.
DOI: 10.1016/j.tetlet.2007.10.116.
Operationally simple and efficient workup procedure for TBAF-mediated desilylation: application to halichondrin synthesis.
Kaburagi Y, Kishi Y
Org Lett. 2007; 9(4):723-6.
PMID: 17286380
PMC: 2519602.
DOI: 10.1021/ol063113h.
